Get the Stockscreener App
3.3788
20.82%
0.5738
Replimune Group Inc stock is traded at $3.3788, with a volume of 3.65M.
It is up +20.82% in the last 24 hours and down -63.28% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$2.805
Open:
$2.74
24h Volume:
3.65M
Relative Volume:
1.29
Market Cap:
$260.17M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-1.0692
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
-73.17%
1M Performance:
-63.28%
6M Performance:
-75.35%
1Y Performance:
-66.24%
1-Day Range:
$2.70
$3.85
1-Week Range:
$2.68
$13.24
52-Week Range:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
3.375 | 955.88M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.57 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.62 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.03 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.39 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.93 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group, Inc. (REPL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Iovance climbs after FDA rejection for Replimune’s skin cancer drug - MSN
Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha
Fraud Investigation Opened: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) on Behalf of Shareholders - ACCESS Newswire
What analysts say about Replimune Group Inc. stockBreakthrough wealth creation - Autocar Professional
Replimune Shares Collapse After FDA Rejects Melanoma Therapy Application - MSN
What drives Replimune Group Inc. stock priceExplosive trading opportunities - Autocar Professional
Replimune receives CRL on BLA for RP1 for advanced melanoma - pharmaphorum
Replimune says FDA rejected its lead drug for skin cancer - MSN
INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC - GlobeNewswire
Lost Money on Replimune Group, Inc. (REPL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
BMO Capital downgrades Replimune stock to Underperform after CRL - Investing.com Australia
Did You Suffer Losses in Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Replimune Group Surges to 445th in Trading Volume with $255 Million Day Despite 77 Percent Stock Drop - AInvest
Barclays downgrades Replimune Group stock rating to Equalweight on FDA rejection - Investing.com
Replimune CRL Could Hold Warning For Accelerated Approvals - insights.citeline.com
Replimune (REPL) Faces Downgrade and Uncertainty in Latest Analy - GuruFocus
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Business Wire
FDA Rejection Shocks Wall Street, And Craters A Stock - Investor's Business Daily
FDA Issues CRL for RP1 in Advanced Melanoma - Targeted Oncology
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
BMO Capital reiterates Outperform rating on Replimune stock despite FDA setback By Investing.com - Investing.com South Africa
REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire
Replimune Group Inc. Stock Analysis and ForecastExceptional market performance - jammulinksnews.com
Market Analysis: July 22nd, 2025 - The Globe and Mail
Leerink Partners downgrades Replimune stock on FDA rejection letter By Investing.com - Investing.com Canada
REPL ALERT: Levi & Korsinsky Investigates Replimune Group, Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL) - Seeking Alpha
Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.
Replimune (REPL) Downgraded to Market Perform by Leerink | REPL Stock News - GuruFocus
Replimune Group Stock Drops Significantly on News of FDA Complete Response LetterKehoe Law Firm, P.C. Investigating Securities Claims on Behalf of InvestorsREPL - ACCESS Newswire
Jefferies lowers Replimune Group stock price target to $6 from $31 - Investing.com India
Replimune drug rejected by FDA; Omega raises $647M biotech fund - BioPharma Dive
Replimune price target lowered to $6 from $31 at Jefferies - TipRanks
Wedbush downgrades Replimune stock to Neutral after FDA rejection By Investing.com - Investing.com South Africa
Barclays maintains Overweight rating on Replimune stock after FDA setback - Investing.com Australia
Replimune Group (REPL) Faces Downgrade with Significant Price Ta - GuruFocus
Replimune Plunges 76.26% Intraday, What Lies Behind the FDA's CRL Rejection? - AInvest
Replimune stock falls after FDA issues CRL for melanoma treatment - Investing.com
Replimune stock falls after FDA issues CRL for melanoma treatment By Investing.com - Investing.com Canada
Wedbush downgrades Replimune stock to Neutral after FDA rejection - Investing.com Australia
JPMorgan downgrades Replimune to Neutral following CRL for cancer drug - TipRanks
BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities - GlobeNewswire
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment - Barron's
Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action Investigation – REPL - Business Wire
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Replimune Group Plunges 73.3% Intraday, What Now for Replimune's Melanoma Gamble? - AInvest
Replimune rocked by CRL for lead candidate - The Pharma Letter
Mizuho analyst comments on Replimune stock decline following CRL By Investing.com - Investing.com Canada
Replimune (REPL) Group Trading Resumes After Halt | REPL Stock N - GuruFocus
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
4.47%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):